Ascendis Pharma A/S(ASND)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ASND Ascendis Pharma A/S

盘后交易 10-19 18:51:27 EDT

229.95

+4.70

+2.09%

盘后228.86

-1.09-0.47%

17:18 EDT

最高233.19	最低225.81	成交量126.81万
今开227.44	昨收225.25	日振幅3.28%
总市值152.20亿	流通市值150.71亿	总股本6,619万
成交额2.91亿	换手率1.93%	流通股本6,554万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":229.95,"timestamp":1792440000000,"preClose":225.25,"halted":0,"volume":1268091,"hourTrading":{"tag":"盘后","latestPrice":228.86,"preClose":229.95,"latestTime":"17:18 EDT","volume":9323,"amount":2143761.47913,"timestamp":1792444732890,"change":-1.09,"changeRate":-0.00474,"amplitude":0.008393},"delay":0,"changeRate":0.02086570477247498,"floatShares":65539518,"shares":66189926,"eps":13.1241,"marketStatus":"盘后交易","change":4.7,"latestTime":"10-19 18:51:27 EDT","open":227.44,"high":233.19,"low":225.81,"amount":291128813.65458,"amplitude":0.032764,"askPrice":235.02,"askSize":200,"bidPrice":225,"bidSize":3,"shortable":3,"etf":0,"ttmEps":13.1241,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792454400000},"marketStatusCode":4,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":225.25,"preHourTrading":{"tag":"盘前","latestPrice":226,"preClose":225.25,"latestTime":"09:00 EDT","volume":106,"amount":23955.56858,"timestamp":1792414806432,"change":0.75,"changeRate":0.00333,"amplitude":0.00192},"postHourTrading":{"tag":"盘后","latestPrice":228.86,"preClose":229.95,"latestTime":"17:18 EDT","volume":9323,"amount":2143761.47913,"timestamp":1792444732890,"change":-1.09,"changeRate":-0.00474,"amplitude":0.008393},"volumeRatio":1.898526,"impliedVol":0.4606,"impliedVolPercentile":0.4143},"requestUrl":"/m/hq/s/ASND/","defaultTab":"news","newsList":[{"id":"1175267190","title":"异动解读｜Ascendis Pharma盘中下跌12.23%，终止与诺和诺德肥胖药合作引发市场抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1175267190","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175267190?lang=zh_cn&edition=full","pubTime":"2026-09-16 00:13","pubTimestamp":1789488801,"startTime":"0","endTime":"0","summary":"9月15日，Ascendis Pharma盘中下跌12.23%，报232.5美元/股，成交额2.97亿美元，跌幅显著超出生物科技板块整体表现。消息面上，公司宣布终止与诺和诺德于2024年达成的合作协议，重新收回其Transcon技术在代谢性疾病及心血管疾病领域的独家权利，同时披露4亿美元股票回购计划。市场担忧主要集中于：终止与全球GLP-1龙头诺和诺德的合作，意味着Ascendis在竞争激烈的肥胖药赛道中将失去重要的商业化协同资源，独立推进代谢管线的研发及商业化风险加大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"终止诺和诺德合作，Ascendis Pharma下跌","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112768036","title":"Ascendis Pharma A/S宣布收回Transcon技术在代谢与心血管疾病领域的独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1112768036","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112768036?lang=zh_cn&edition=full","pubTime":"2026-09-15 06:02","pubTimestamp":1789423329,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S——这一生物制药领域的先锋企业，近日发布重大战略举措：将重新收回其Transcon技术在代谢性疾病及心血管疾病治疗领域的独家使用权。此举标志着公司在核心治疗领域的布局进入全新阶段，彰显了其对这一前沿技术平台的深度掌控与长期承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ASND","LU0320765992.SGD","MEDI","LU0889565916.HKD","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198670617","title":"异动解读｜Ascendis Pharma盘中上涨5.92%，与BioMarin就Yuviwel达成全球专利和解","url":"https://stock-news.laohu8.com/highlight/detail?id=1198670617","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198670617?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:48","pubTimestamp":1788184115,"startTime":"0","endTime":"0","summary":"8月31日，Ascendis Pharma盘中上涨5.92%，报262.0美元/股，成交额3316.58万美元。消息面上，公司宣布与BioMarin签署具有约束力的条款清单，就Yuviwel达成全球和解及许可协议，终结双方在美国、德国、丹麦、巴西及韩国的所有专利诉讼。BioMarin亦将撤销ITC调查。此前市场对Yuviwel的知识产权不确定性持续担忧，此次和解彻底消除了该产品的专利诉讼风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ascendis Pharma上涨，专利和解扫清推广障碍","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168094828","title":"Ascendis 与 BioMarin 签署约束性条款清单，就 Yuviwel®（Navepegritide）达成全球和解及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1168094828","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168094828?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:03","pubTimestamp":1788174216,"startTime":"0","endTime":"0","summary":"Ascendis 与 BioMarin 宣布，双方已正式签署一份具有约束力的条款清单，旨在于全球范围内就 Yuviwel®（Navepegritide）相关事宜达成全面和解与许可安排。此举标志着两家公司围绕该产品展开的长期纠纷或合作谈判进入关键性的实质性阶段，为后续正式协议的最终落地奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ASND","LU0889565916.HKD","MEDI","LU0109394709.USD","LU0320765992.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152003599","title":"拜玛林制药盘前股价攀升5.6%，宣布与Ascendis Pharma达成全球和解","url":"https://stock-news.laohu8.com/highlight/detail?id=1152003599","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152003599?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:38","pubTimestamp":1788165495,"startTime":"0","endTime":"0","summary":"拜玛林制药（Biomarin Pharmaceutical）的股价在盘前交易时段上扬5.6%。这一涨幅源于公司宣布已与Ascendis Pharma达成全球和解协议。市场对这一消息反应积极，推动股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU0109394709.USD","IE00B7SZLL34.SGD","LU0320765992.SGD","ASND","BMRN","MEDI","BK4139","LU0889565916.HKD","BK4585","IE0002270589.USD","IE00B19Z3581.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172567405","title":"拜玛林制药将撤销ITC调查；包括多国诉讼在内的所有知识产权索赔已解决","url":"https://stock-news.laohu8.com/highlight/detail?id=1172567405","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172567405?lang=zh_cn&edition=full","pubTime":"2026-08-31 14:02","pubTimestamp":1788156130,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布，将撤销美国国际贸易委员会（ITC）的调查。该公司表示，所有知识产权相关主张均已得到解决，其中涵盖了在多个国家进行的诉讼。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4585","IE00B19Z3581.USD","IE0002270589.USD","MEDI","BMRN","IE00B7SZLL34.SGD","LU0320765992.SGD","BK4566","ASND","BK4139","IE00B19Z3B42.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105998184","title":"Ascendis将在ISDS 2026大会上口头报告Transcon® CNP（Navepegritide）关键试验第104周数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1105998184","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105998184?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:19","pubTimestamp":1787689146,"startTime":"0","endTime":"0","summary":"8月25日（路透社）——Ascendis Pharma A/S宣布，其将在ISDS 2026会议上，就Transcon® CNP（Navepegritide）关键性试验的第104周数据，进行口头报告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ASND","LU0320765992.SGD","MEDI","LU0889565916.HKD","LU0109394709.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192773222","title":"Ascendis将在ISDS 2026上口头报告TransCon® CNP（Navepegritide）关键试验第104周数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1192773222","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192773222?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:02","pubTimestamp":1787688132,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S宣布，将在2026年国际生长障碍学会会议上，以口头报告形式展示其关键性试验中TransCon CNP的第104周数据。TransCon CNP是一种长效C型利钠肽前体药物，旨在通过每月一次给药来持续维持药物暴露水平，从而解决儿童软骨发育不全患者未被满足的医疗需求。此次数据的发布，有望进一步巩固Ascendis在罕见内分泌疾病领域的领先地位。Ascendis管理层表示，对即将公布的数据充满信心，并期待与全球专家共同探讨这一创新疗法的未来潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","ASND","BK4139","BK4585","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152272597","title":"Eyconis启动Eyc-0305首次人体临床试验，针对未经治疗的湿性年龄相关性黄斑变性患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1152272597","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152272597?lang=zh_cn&edition=full","pubTime":"2026-08-18 20:01","pubTimestamp":1787054477,"startTime":"0","endTime":"0","summary":"Eyconis公司今日宣布，已正式启动Eyc-0305的首次人体临床试验，该试验专门面向未经治疗的湿性年龄相关性黄斑变性患者。此次启动的临床试验将重点评估Eyc-0305在患者群体中的安全性、耐受性及初步疗效。公司研发团队对Eyc-0305的潜力充满信心，认为其有望在未来改变湿性年龄相关性黄斑变性的治疗格局。Eyc-0305若能在临床试验中取得成功，不仅将为患者带来福音，也可能为Eyconis公司在竞争激烈的眼科药物市场中赢得重要席位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MEDI","ASND","LU0320765992.SGD","BK4585","LU0109394709.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130334756","title":"安全性与耐受性稳定：Ascendis Pharma A/S 单药与联合疗法表现一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1130334756","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130334756?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:15","pubTimestamp":1786018511,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S 在近期发布的数据中表明，其单药治疗与联合治疗的安全性和耐受性表现持续稳定。这一结果进一步巩固了市场对该公司在生物制药领域研发能力的信心，特别是在药物安全性与患者耐受性方面，未出现显著差异。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","ASND","MEDI","LU0320765992.SGD","LU0889565916.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152547834","title":"Ascendis公布Coach项目第78周结果，更新软骨发育不全项目进展与Yuviwel®美国市场吸收情况","url":"https://stock-news.laohu8.com/highlight/detail?id=1152547834","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152547834?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:02","pubTimestamp":1786017742,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S（简称Ascendis）近日披露了其Coach项目在第78周的关键数据，同时就软骨发育不全相关研发项目及Yuviwel®在美国市场的渗透情况，提供了最新动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","LU0109394709.USD","BK4139","LU0889565916.HKD","BK4585","LU0320765992.SGD","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187464751","title":"异动解读｜Ascendis Pharma盘中上涨8.3%，核心药物长期临床数据亮眼叠加分析师看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1187464751","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187464751?lang=zh_cn&edition=full","pubTime":"2026-06-26 00:16","pubTimestamp":1782404163,"startTime":"0","endTime":"0","summary":"6月25日，Ascendis Pharma盘中上涨8.3%，报259.16美元/股，成交额3.27亿美元。消息面上，公司近期公布了核心产品Yorvipath治疗甲状旁腺功能减退症的多项长期数据，市场持续消化利好。三期PaTHway研究3.5年数据显示综合应答率达86%，89%患者完成试验；二期PaTH Forward研究5年数据显示应答率82%，肾功能持续改善。Wedbush发布研报称Yorvipath相较竞品保持显著优势，维持跑赢大市评级及273美元目标价。此外，竞争对手MBX Biosciences同适应症药物二期应答率仅57%，进一步凸显Yorvipath的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169083837","title":"MBX核心药物试验结果符合预期，但部分投资者或期待更高——市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1169083837","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169083837?lang=zh_cn&edition=full","pubTime":"2026-06-13 01:22","pubTimestamp":1781284950,"startTime":"0","endTime":"0","summary":"MBX Biosciences公布了其用于治疗甲状旁腺功能减退症的药物canvuparatide的二期试验结果，随后股价下跌5.5%。瑞穗银行的分析指出，该药物在52周时达到了57%的综合应答率，这是衡量治疗成功的关键指标，与其竞争对手Yorvipath的64%水平相当。然而，分析人士认为，部分投资者可能会提出异议，因为在与患者使用相关的更宽松标准下，Yorvipath的实际基准应答率可能高达80%。尽管如此，分析师们对此次试验结果以及canvuparatide每周一次的给药方案仍持乐观态度。该方案可将注射次数减少86%，他们表示，这“继续支持canvuparatide的商业潜力”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MBX","LU0320765992.SGD","LU0109394709.USD","BK4007","BK4585","ASND","ISBC","BK4211","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518208844","title":"Ascendis Pharma A/S盘中异动 急速下跌5.16%报138.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208844","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518208844?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:43","pubTimestamp":1741624985,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日00时43分，Ascendis Pharma A/S股票出现异动，股价快速下挫5.16%。截至发稿，该股报138.22美元/股，成交量11.4887万股，换手率0.19%，振幅3.85%。Ascendis Pharma A/S股票所在的生物技术行业中，整体涨幅为0.67%。Ascendis Pharma A/S公司简介：Ascendis Pharma AS是一家生物制药公司，应用其TransCon技术平台为患者带来有意义的改变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311004306abf34219&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311004306abf34219&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","BK4585","LU0889565916.HKD","LU0109394709.USD","BK4139","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514097967","title":"坎托菲茨杰拉德公司：维持Ascendis Pharma(ASND.US)评级，由增持调整至增持评级, 目标价由170.00美元调整至200.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097967","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514097967?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:22","pubTimestamp":1740493354,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：维持Ascendis Pharma(ASND.US)评级，由增持调整至增持评级, 目标价由170.00美元调整至200.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25222248383563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512611921","title":"Ascendis Pharma A/S盘中异动 早盘股价大涨5.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512611921","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512611921?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:31","pubTimestamp":1739892667,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时31分，Ascendis Pharma A/S股票出现异动，股价急速拉升5.50%。截至发稿，该股报152.00美元/股，成交量16.6641万股，换手率0.28%，振幅4.35%。Ascendis Pharma A/S股票所在的生物技术行业中，整体涨幅为0.59%。Ascendis Pharma A/S公司简介：Ascendis Pharma AS是一家生物制药公司。该公司的产品线包括 Transcon 生长激素、Transconpeptides、Transcon PTH、Transcon CNP 等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218233107abd3bcfd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218233107abd3bcfd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0109394709.USD","BK4585","LU0320765992.SGD","ASND","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511704046","title":"Ascendis Pharma A/S2024财年实现净利润-4.09亿美元，同比增加21.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511704046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511704046?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:01","pubTimestamp":1739635295,"startTime":"0","endTime":"0","summary":"2月16日，Ascendis Pharma A/S公布财报，公告显示公司2024财年净利润为-4.09亿美元，同比增加21.35%；其中营业收入为3.93亿美元，同比增加36.46%，每股基本收益为-7.06美元。从资产负债表来看，Ascendis Pharma A/S总负债13.31亿美元，其中短期债务5.09亿美元，资产负债比为0.92，流动比率为1.17。机构评级：截至2025年2月16日，当前有16家机构对Ascendis Pharma A/S目标价做出预测，其中目标均价为201.57美元，其中最低目标价为162.69美元，最高目标价为290.23美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000204abd030f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000204abd030f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511957350","title":"高盛：维持Ascendis Pharma(ASND.US)评级，由买入调整至买入评级, 目标价由200.00美元调整至225.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511957350","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511957350?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:38","pubTimestamp":1739468289,"startTime":"0","endTime":"0","summary":"高盛：维持Ascendis Pharma(ASND.US)评级，由买入调整至买入评级, 目标价由200.00美元调整至225.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14013848150593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511525165","title":"Ascendis Pharma A/S盘中异动 大幅拉升12.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511525165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511525165?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:31","pubTimestamp":1739457116,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时31分，Ascendis Pharma A/S股票出现异动，股价快速上涨12.79%。截至发稿，该股报142.27美元/股，成交量12.7929万股，换手率0.21%，振幅3.97%。Ascendis Pharma A/S股票所在的生物技术行业中，整体跌幅为0.01%。Ascendis Pharma A/S公司简介：Ascendis Pharma AS是一家生物制药公司。该公司的产品线包括 Transcon 生长激素、Transconpeptides、Transcon PTH、Transcon CNP 等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223156abcdb23a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213223156abcdb23a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0109394709.USD","BK4585","LU0889565916.HKD","ASND","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168353386","title":"异动解读 | Ascendis Pharma A/S股价盘后大涨6.03%,业绩超预期是推手","url":"https://stock-news.laohu8.com/highlight/detail?id=1168353386","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168353386?lang=zh_cn&edition=full","pubTime":"2025-02-13 05:38","pubTimestamp":1739396317,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S在今日盘后交易中股价大涨6.03%,引发市场广泛关注。这家生物科技公司业绩向好的因素推动了股价的上涨。\n\n值得一提的是,Ascendis Pharma在2024年第四季度交出了亮眼的成绩。数据显示,该公司2024年第四季度GAAP每股收益为€-0.64,远好于分析师预期的€-1.07;销售额为€1.73916亿,也高于预期的€1.11178亿。\n\n这一超预期的业绩表现极大增强了投资者对Ascendis Pharma未来发展的信心,市场普遍看好该公司的增长前景。这成为推动公司股价在盘后大涨6.03%的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ASND"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":-0.0174},{"period":"1month","weight":-0.0906},{"period":"3month","weight":-0.137},{"period":"6month","weight":-0.0787},{"period":"1year","weight":0.088},{"period":"ytd","weight":0.0563}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ascendis Pharma A/s成立于2006年9月21日。该公司是一家临床阶段的生物制药公司，该公司运用其TransCon技术开发具有最佳的长效药物疗法的管道以解决大市场显著未满足的医疗需求。该公司正在开发其先导候选产品，TransCon人生长激素或生长激素TransCon，每周一次给药治疗生长激素缺乏症以及其他疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.031281},{"month":2,"riseRate":0.583333,"avgChangeRate":0.050705},{"month":3,"riseRate":0.416667,"avgChangeRate":0.030446},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.031037},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.005122},{"month":6,"riseRate":0.666667,"avgChangeRate":0.035016},{"month":7,"riseRate":0.583333,"avgChangeRate":-0.006819},{"month":8,"riseRate":0.75,"avgChangeRate":0.084399},{"month":9,"riseRate":0.583333,"avgChangeRate":0.025323},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.009936},{"month":11,"riseRate":0.818182,"avgChangeRate":0.047363},{"month":12,"riseRate":0.545455,"avgChangeRate":0.041981}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ascendis Pharma A/S(ASND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ascendis Pharma A/S(ASND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}